Drugs / AN2-502998
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07024589 | Aug 2025 → Mar 2026 | — | AN2 Therapeutics, Inc | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-06-04 | AN2 Therapeutics, Inc | Results AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease an2therapeutics.com ↗
In NHPs with naturally acquired, chronic T. cruzi parasite infection, 28 days of AN2-502998 treatment resulted in 100% parasitic elimination at target exposures attainable in humans, through four months following the end of treatment. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-06-04 | AN2 Therapeutics, Inc | AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease an2therapeutics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AN2-502998 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07024589 ↗ |
| Route | Oral | “Oral Capsule” NCT07024589 ↗ |